Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS20047210HPVENSG00000179546.5protein_codingHTR1DNoNo3352P28221
TVIS44015624HTLV-1ENSG00000179546.5protein_codingHTR1DNoNo3352P28221
TVIS44043967HTLV-1ENSG00000179546.5protein_codingHTR1DNoNo3352P28221
TCGA Plot Options
Drug Information
GeneHTR1D
DrugBank IDDB00696
Drug NameErgotamine
Target IDBE0000659
UniProt IDP28221
Regulation Typeagonist
PubMed IDs12558771; 8384716; 1407010; 14504136; 1646776
CitationsSilberstein SD, McCrory DC: Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003 Feb;43(2):144-66.@@Lovenberg TW, Erlander MG, Baron BM, Racke M, Slone AL, Siegel BW, Craft CM, Burns JE, Danielson PE, Sutcliffe JG: Molecular cloning and functional expression of 5-HT1E-like rat and human 5-hydroxytryptamine receptor genes. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2184-8.@@Hoyer D, Lery H, Waeber C, Bruinvels AT, Nozulak J, Palacios JM: "5-HT1R" or 5-HT1D sites? Evidence for 5-HT1D binding sites in rabbit brain. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):249-54.@@Sanchez-Lopez A, Centurion D, Vazquez E, Arulmani U, Saxena PR, Villalon CM: Pharmacological profile of the 5-HT-induced inhibition of cardioaccelerator sympathetic outflow in pithed rats: correlation with 5-HT1 and putative 5-ht5A/5B receptors. Br J Pharmacol. 2003 Oct;140(4):725-35. Epub 2003 Sep 22.@@Deliganis AV, Peroutka SJ: 5-Hydroxtryptamine1D receptor agonism predicts antimigraine efficacy. Headache. 1991 Apr;31(4):228-31.
GroupsApproved
Direct ClassificationErgotamines, dihydroergotamines, and derivatives
SMILES[H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O
Pathways
PharmGKBPA164747651
ChEMBLCHEMBL442